Nevertheless, the impaired myeloid cell mediated antibacterial defense caused by Btk deficiency we report here, may explain the recurrent respiratory tract infections in patients with XLA on IVIG treatment and the increased susceptibility to infections in patients treated with ibrutinib (9, 11). Here, BTK is linked to infection.